Oded Biran - Rosetta Genomics Insider

ROSG -- USA Stock  

USD 0.43  0.0001  0.0233%

General Counsel

Mr. Oded Biran serves as General Counsel of the company, since November, 2011. Mr. Biran was an independent attorney between the years 20102011, after previously working for us as legal counsel between June and November 2010. Prior to that, Mr. Biran was an associate in the law offices of Sharon Raviv and Co., a boutique law firm specializing in technology and communications, between December 2009 and June 2010. During the years of 2008 and 2009, Mr. Biran was an associate in Raved Magriso, Benkel, Lahav and Co.s, where he practiced in the corporate and securities department, specializing in corporate, technology, IP and complex mergers and acquisitions transactions. During 20062007, Mr. Biran was an associate at Gabriel Reubinoff and Co.s Tel Aviv office where he coheaded the firms class action department
Age: 35  Executive Since 2011      
972 73 222 0700  http://www.rosettagx.com
Biran holds a L.L.B degree from the Hebrew University in Jerusalem and is a member of the Israeli Bar Association.

Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (137.95) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics Ltd has Current Ratio of 2.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people.Rosetta Genomics Ltd (ROSG) is traded on Nasdaq Capital Markets in USA. It is located in ISRAEL and employs 86 people. Rosetta Genomics is listed under Pharmaceutical Products category by Fama And French industry classification.

Rosetta Genomics Leadership Team

David Sidransky, Director
Kenneth Berlin, CEO
Anne Fields, Executive
Joshua Rosensweig, Director
Dganit Bar, Executive, Ph.D
Brian Markison, Chairman
Douglas Sites, President
Tal YaronEldar, Director, MBA
Eti Meiri, President, Ph.D
Robert Wassman, Executive
Oded Biran, Executive
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director
Ron Kalfus, CFO
Gerald Dogon, Director
Tali YaronEldar, Director, MBA

Stock Performance Indicators

Current Sentiment - ROSG

Rosetta Genomics Investor Sentiment
Most of Macroaxis users are at this time bullish on Rosetta Genomics Ltd. What is your perspective on investing in Rosetta Genomics Ltd? Are you bullish or bearish?
98% Bullish
2% Bearish

Trending Equities

Currently Active Assets on Macroaxis
Purchased over 100 shares of
few days ago
Traded for 10.44
Purchased over 300 shares of
few days ago
Traded for 6.24
Purchased over 70 shares of
few days ago
Traded for 23.42
Purchased over 200 shares of
few days ago
Traded for 8.1
Purchased over 400 shares of
few days ago
Traded for 4.74
Additionally take a look at Your Equity Center. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.